Review on Diabetes Mellitus

Pratibha R.Vannarwad, Akshata B. Lasure, Nandkishor B.Bavage, Shyamlila B.Bavage
[1]*B.Pharmacy Final Year ,Latur College of Pharmacy, Hasegaon*
[2]*Department of Pharmaceutical Analysis, Latur College of Pharmacy, Hasegaon*
[3]*Department of Pharmaceutical Analysis, Latur College of Pharmacy, Hasegaon*
[4]*Departmemt of Pharmacognosy, Latur College of Pharmacy, Hasegaon, Tq.Ausa Dist. Latur 413512, Maharashtra, India*

Abstract - **Diabetes mellitus may be a cluster of metabolic diseases characterized by hyperglycemia ensuing from defects in hypoglycemic agent secretion, hypoglycemic agent action, or both. The chronic hyperglycemia of diabetes is associated with semi-permanent harm, dysfunction, and failure of varied organs, especially the eyes, kidneys, nerves, heart, and blood vessels.**

Several unhealthful processes square measure concern within the development of diabetes. These vary from autoimmune destruction of the beta-cells of the exocrine gland with ensuant insulin deficiency to abnormalities that lead to resistance to insulin action. In the latter, class a degree of hyperglycemia enough to cause pathologic and purposeful changes in varied target tissues, However while not clinical symptoms, may be present for a long period of time before polygenic disease is recognize. Throughout this asymptomatic period, it is doable to demonstrate an abnormality in macromolecules metabolism by measure of plasma aldohexone in the fasting state or after a challenge with an oral aldohexone load. The degree of hyperglycemia (if any) could amendment over time, looking on the extent of the basic disease process . An illness method could also be gift however might not have progressed far enough to cause hyperglycemia. The same disease process can cause impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) while not fulfilling the standards for the diagnosis of polygenic disease . In some specific with diabetes, adequate glycemic control can be achieved with weight reduction, exercise, and/or oral aldohexone lowering agents. These individuals therefore do not require insulin. Other individuals who have some residual hypoglycemic agent secretion but require exogenous insulin for adequate glycemic control can survive without it. Individuals with extensive beta-cell destruction and therefore no residual insulin secretion need hypoglycemic agent for survival. The seriousness of the metabolic abnormality will progress, regress, or keep an equivalent. Thus, the degree of hyperglycemia reflects the severity of the underlying biological process and its treatment quite the character of the strategy itself.

Index Terms - **Diabetes mellitus,type 1diabetes mellitus, type 2 diabetes mellitus, gastational diabetes mellitus, insulin.**

CLASSIFICATION OF DM AND OTHER CATEGORIES OF ALDOHEXONE REGULATIONS

Assigning a sort of polygenic disease to a private typically depends on the circumstances existing at the time of diagnosing, and many diabetic individuals do not easily suitable into a single class. For example, a person with physiological condition diabetes mellitus (GDM) could still be hyperglycemic when delivery and should be regulated to own, in fact, type 2 diabetes. Instead, someone who gain polygenic disease because of massive doses of exogenous steroids may become normoglycemic once the glucocorticoids are discontinued, but then may expand diabetes many years later after recurrent episodes of pancreatitis. Another sample would be a someone treated with thiazide who develops polygenic disease years later. As a result of thiazide in themselves rarely cause severe hyperglycemia, such people most likely have type 2 diabetes that's execrated by the drugs. Thus, for the practitioner and patient, it's shorter to label the particular type of polygenic disease than it's to know the pathological process of the hyperglycemia and to treat it successfully.

TYPE 1 DIABETES MELLITUS

Immune-mediated diabetes:
This form of polygenic disease, which reports for only 5–10% of those with diabetes, previously encompassed by the terms hypoglycemic agent independent diabetes, type I diabetes, or juvenile-

onset polygenic disease, results from acellular-mediated autoimmune demolition of the beta cells of the pancreas. Markers of the immune destruction of the Beta-cell involve islet cell autoantibodies, autoantibodies to insulin, autoantibodies to glutamic acid decarboxylase (GAD65),and autoantibodies to the tyrosine phosphatases IA-2 and IA-2. One and unremarkably addition of those autoantibodies is present in 85–90% of people once abstinence hyperglycemia is initially recognize. Also, the disease has strong HLA associations, with association to the DQA and DQB genes, and it is induced by the DRB genes. These HLA-DR/DQ alleles can be either predisposing or preventive .in this form of diabetes, the rate of Beta-cell destruction is entirely irregular, being quick in some individuals (mainly infants and children) and slow in others (mainly adults). Some patients, especially children and adolescents, may present with diabetic acidosis as the first demonstration of the disease. Others have modest fasting hyperglycemia that can quickly change to severe hyperglycemia and/or diabetic acidosis in the presence of infection or other stress. Still others, especially adults, may keep residual beta-cell function sufficient to inhibit ketoacidosis for many years; such individuals ultimately become dependent on insulin for survival and are at risk for ketoacidosis. At this latter phase of the polygenic disease, there is little or no hypoglycemic agent secretion, as manifested by low or undetectable levels of plasma C-peptide. Immune-mediated diabetes often occurs in childhood and adolescence, but it can happen at any age, even in the 8th and 9th decades of life. Autoimmune demolition of alfa-cells has multiple genetic predispositions and is also connected to environmental factors that are still poorly defined. Although patients are hardly obese when they present with this type of diabetes, the presence of obesity is not incompatible with the diagnosis. These patients are also susceptible to other autoimmune disorders such as Graves' disease, Hashimoto's thyroiditis, Addison's disease, vitiligo, celiac sprue, autoimmune hepatitis, myasthenia gravis, and pernicious anemia. Idiopathic diabetes. Some forms of type 1 polygenic disease have no familiar etiologies. Some of these patients have permanent insulinopenia and are prone to diabetic acidosis but have no evidence of autoimmunity. Although only a minority of patients with type 1 diabetes fall into this group, of those who do, most are of African or Asian ancestry. Individuals with this form of polygenic disease suffer from episodic diabetic acidosis and exhibit varying degrees of insulin deficiency between episodes. This form of diabetes is strongly inherited, lacks immunological evidence for -cell autoimmunity, and is not HLA associated.An absolute requirement for insulin replacing therapy in affected patients may come and go.

TYPE 2DIABETES MELLITUS

(Ranging from preponderantly hypoglycemic agent resistance with relative hypoglycemic agent deficiency to preponderantly associate degree insulin humour deficiency with insulin resistance) this type of polygenic disease, that reports for 90-95% of these with polygenic disease an recently mentioned to as ketosis resistance diabetes mellitus, type 2 DM, type 2 polygenic disease encompasses people on agency have hypoglycemic agent resistance and frequently have relative hypoglycemic agent deficiency a minimum of at first and infrequently throughout their period of time, these people don't would like insulin treatment to survive. These are unit in all probability many alternative causes of this type of polygenic disease. Through the precise etiologies don't seem to be illustrious, response destruction of beta cells doesn't occur ,and patients don't have any of the opposite cause of diabetes listed higher than below most patients with this type of diabetes mellitus area unit fat ,and fleshiness itself cause a point of hypoglycemic agent resistance. Patients un agency don't seem to be fat by ancient weight criteria might have associate degree inflated shore of body fat distributed preponderantly within the abdominal region acidosis rarely happens ad lib during this style of diabetes, once seen, it always arises in association with in the strain of another malady like infection, this type of polygenic disease often goes unknown for several years as a result of the hypoglycemia develops step by step and at earlier stages is usually not severe enough for the patient to note any of the classic symptoms of polygenic disease nonetheless such patients unit of inflated risk of developing macrovascular and microvascular complications. Whereas patients with this type of polygenic disease might have hypoglycemic agent levels that seem traditional or elevated, the higher blood glucose levels in these polygenic disease patients would be expected to end

in even higher hypoglycemic agent values had their beta-cell operate been normal. Thus, hypoglycemic agent secretion is defective in these patients and insufficient to compensate for hypoglycemic agent resistance. Hypoglycemic agent resistance could improve with weight reduction and/or medicine treatment of hyperglycemia however is seldom restored to normal. The risk of developing this form of polygenic disease increases with age, obesity, and lack of physical activity. It happens a lot of times in girls with previous GDM and in people with high blood pressure or dyslipidemia, and its frequency varies in numerous racial/ethnic subgroups. It is often associated with a Powerful genetic predisposition, a lot of thus than is the autoimmune form of type 1 polygenic disorder. However, the genetics of this form of diabetes are complex and not clearly defined. Many kind of polygenic disease Genetic defects of the beta-cell. Several forms of polygenic disease are related with monogenetic defects in beta cell function. These kind of polygenic disease are oftentimes characterized by onset of hyperglycemia at an early age (generally before age twenty five years). They are referred to as maturity-onset diabetes of the young (MODY) and are characterized by impaired hypoglycemic agent secretion with minimal or no defects in insulin action. They are inherited in an autosomal dominant pattern. Abnormalities at six genetic loci on different chromosomes have been identified to date. The most common form is associated with mutations on chromosome 12 in hepatic transcription factor referred to as hepatocyte nuclear factor (HNF)-1alfa. A second type is related to mutations in the glucokinase gene on chromosome 7p and leads to in a defective glucokinase molecule. Glucokinase converts aldohexone to glucose-6-phosphate, the metabolism of which, in turn, stimulates hypoglycemic agent secretion by the -cell. Thus, glucokinase serves as the "glucose sensor" for the beta-cell. As a result of defects within the glucokinase gene, increased plasma levels of aldohexone are necessary to elicit normal levels of hypoglycemic agent secretion. The less common forms result from mutations in other transcription factors, including HNF-4HNF-1, hypoglycemic agent promoter factor (IPF)-1, and NeuroD1. Point mutations in mitochondrial DNA have been found to be associated with polygenic disease and deafness The most common mutation occurs at position 3243 in the tRNA leucine gene, leading to an A-to-G transition. An even lesion happens with in the MELAS syndrome (mitochondrial pathology, brain disorder , lactic acidosis, and stroke-like syndrome); but polygenic disorder isn't a part of this syndrome, suggesting different phenotypic expressions of this genetic lesion. Genetic abnormalities that result in the inability to convert proinsulin to hypoglycemic agent have been identified in a few families, and such traits are inherited in an autosomal dominant pattern. The resultant glucose intolerance is mild. Similarly, the assembly of mutant hypoglycemic agent molecules with resultant impaired receptor binding has additionally been known in a few families and is associated with an autosomal inheritance and only mildly impaired or even normal glucose metabolism. Genetic defects in hypoglycemic agent action. There are unusual causes of polygenic disease that result from genetically determined abnormalities of hypoglycemic agent action. The metabolic abnormalities associated with mutations of the hypoglycemic agent receptor may range from hyperinsulinemia and modest hyperglycemia to severe polygenic disease . Some individuals with these mutations may have acanthosis nigricans. Ladies could also be virilized and have enlarged, cystic ovaries. Within the past, this syndrome was termed blood type endocrine. Leprechaunism and also the Rabson-Mendenhall syndrome are two pediatric syndromes that have mutations within the insulin receptor gene with subsequent alterations in insulin receptor perform and extreme endocrine resistance. The former has characteristic facial features and is usually fatal in infancy, while the latter is associated with abnormalities of teeth and nails and pineal gland hyperplasia. Alterations in the structure and function of the insulin receptor can't be identified in patients with hypoglycemic agent -resistant lipoatrophic polygenic disease. Therefore, it is assumed that the lesion(s) must reside in the postreceptor signal transduction pathways. Diseases of the exocrine pancreas. Any process that diffusely injures the exocrine gland can cause polygenic disorder. Acquired processes include pancreatitis, trauma, infection, pancreatectomy, and pancreatic carcinoma. With the exception of that caused by carcinoma, harm to the exocrine gland must be extensive for polygenic disease to occur; adreno carcinoma that involve only a small portion of the exocrine gland have been associated with polygenic disease . This implies a

mechanism other than simple reduction in cell mass. If extensive enough, pancreatic fibrosis and hemochromatosis will also harm beta-cells and impair insulin secretion. Fibrocalculous pancreatopathy could also be amid abdominal pain diverging to the rear and duct gland calcifications known as X-ray examination. Pancreatic fibrosis and calcium stones in the exocrine ducts have been identified at autopsy. Endocrinopathies. Several hormones (e.g., growth hormone, cortisol, glucagon, epinephrine) antagonize hypoglycemic agent action. Extra amounts of these hormones (e.g., acromegaly, Cushing's syndrome, glucagonoma, pheochromocytoma, respectively) can cause diabetes. This generally occurs in individuals with preexisting defects in hypoglycemic agent secretion, and hyperglycemia typically resolves when the hormone excess is resolved. Somatostatinoma- and aldosterone-induced hypokalemia can cause polygenic disease , at least in part, by inhibiting hypoglycemic agent secretion. Hyperglycemia generally resolves after successful removal of the tumor. Drug- or chemical-induced polygenic disorder. Many medicines can impair hypoglycemic agent secretion. These drugs may not cause diabetes by themselves, but they may precipitate polygenic disorder in individuals with hypoglycemic agent resistance. In such cases, the classification is unclear because the sequence or relative importance of beta-cell dysfunction and hypoglycemic agent resistance is unknown. Certain toxins such as Vacor (a rat poison) and intravenous pentamidine can permanently destroy exocrine gland beta-cells. Such drug reactions fortunately are rare. There are also many drugs and hormones that can impair hypoglycemic agent action. Examples include vitamin B and glucocorticoids. People receiving interferon have been reported to develop polygenic disease associated with islet cell antibodies and, in certain instances, severe hypoglycemic agent deficiency. The list shown in Table one is not all inclusive but reflects the more commonly known drug.

Table 1 etiological classification of DM:

I. Type 1 DM (beta-cell destruction, typically results in absolute insulin deficiency.)

A. Immune mediate

B. Idiopathic

II. Type 2 DM (may vary from predominantly hypoglycemic agent resistance with relative internal secretion deficiency to a predominantly secretory defect with insulin resistance)

III. Alternative specific types

A. Genetic defects of beta-cell operate

1. Body 12, HNF-1alfa (MODY3)
2. Body 7, glucokinase (MODY2)
3. Body 20, HNF-4alfa (MODY1)
4. Body 13, insulin promoter factor-1 (IPF-1; MODY4)
5. Body 17, HNF-1beta (MODY5)
6. Body 2, NeuroD1 (MODY6)
7. Mitochondrial deoxyribonucleic acid
8. Others

B. Genetic defects in internal secretion action

1. Type A insulin resistance
2. Leprechaunism
3. Rabson-Mendenhall syndrome
4. Lipoatrophic polygenic disease
5. Others

C. Diseases of the exocrine gland

1. Inflammation
2. Trauma/pancreatectomy
3. Neoplasia
4. Monogenic disorder
5. Pathology
6. Fibrocalculous pancreatopathy
7. Others

D. Endocrinopathies

1. Acromegaly
2. Cushing's syndrome
3. Glucagon glucoma
4. 4.Tumor
5. Acidosis
6. Somatostatinoma
7. Aldosteronoma
8. Others

E. Drug- or chemical-induced

1. Vacor
2. Pentamidine
3. Vitamin B
4. Glucocorticoids
5. Thyroid hormone
6. Diazoxide
7. 7.alfa -adrenergic agonists

8. Thiazides
9. Dilantin
10. Alfa antiviral
11. Others

F. Infections
1. Innate German measles
2. Herpes
3. Others

G. Uncommon kind of immune-mediated polygenic disease
1. "Stiff-man" syndrome
2. Anti–insulin receptor antibodies
3. Others

H. Alternative genetic syndromes typically related to polygenic disease
1. Down's syndrome
2. Klinefelter's syndrome
3. Turner's syndrome
4. Wolfram's syndrome
5. Friedreich's neurological disease
6. Huntington's chorea
7. Laurence-Moon-Biedl syndrome
8. Myotonic atrophica
9. Porphyria
10. Prader-Willi syndrome
11. Others

IV. Physiological state diabetes mellitus (GDM)

Physiological state diabetes mellitus/gastational diabetes mellitus:

GDM is outlined as any stage of aldohexone intolerance with onset or 1st identification throughout physiological state. The definition applies regardless of whether hypoglycemic agent or solely diet improvement is employed for treatment or whether the condition continue after pregnancy. It doesn't eliminate the prospect that unrecognized aldohexone difference might have antedated or begun concomitantly with the pregnancy. GDM involved -4% of all pregnancies in the U.S., resulting in -135,000 cases annually. The prevalence could vary from 1 to 14% of pregnancies, betting on the population studied. GDM replace nearly 90% of all pregnancies sophisticated by polygenic disease .Deterioration of aldohexone tolerance happen normally during pregnancy, particularly in the third trimester.

REFERENCE

[1] The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197,1997

[2] The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160– 3167, 2003

[3] Carpenter MW, Coustan DR: Criteria for screening tests for Physiological state diabetes. Am J Obstet Gynecol 144:768–773, 1982

[4] O'Sullivan JB, Mahan CM: Criteria for the oral aldohexone tolerance test in pregnancy.Diabetes 13:278, 1964

[5] American Diabetes Association. 2003. Report of the expert committee on the diagnosis and categories of polygenic disease . Diabetes Care. 26(Suppl. 1):S5–S20.

[6] Naylor, C.D., Sermer, M., Chen, E., and Sykora, K. 1996. Cesarean delivery in relation to birth weight and gestational aldohexone tolerance: pathophysiology or practice style? JAMA. 275:1165–1170.

[7] Magee, M.S., Walden, C.E., Benedetti, T.J., and Knopp, R.H. 1993. Influence of diagnostic criteria on the incidence of Physiological state diabetes and perinatal morbidity. JAMA. 269:609–615.

[8] Schmidt, M.I., et al. 2001. Gestational polygenic disorder diagnosed with a 2-h 75-g oral aldohexone tolerance test and adverse pregnancy outcomes. Diabetes Care. 24:1151–1155.

[9] Pettitt, D.J., and Knowler, W.C. 1998. Long-term result of the intrauterine environment, birth weight, and breast-feed on Pima Indians. Diabetes Care. 21(Suppl. 2):B138–B141.

[10] Silverman, B.L., Rizzo, T.A., Cho, N.H., and Metzger, B.E. 1998. Long-term effects of the intrauterine environment. The Northwestern University Diabetes in Pregnancy Center. Diabetes Care.21(Suppl. 2):B142–B149.

[11] Vohr, B.R., McGarvey, S.T., and Tucker, R. 1999. Effects of maternal physiological state polygenic disease on offspring adiposity at 4-7 years of age. Diabetes Care.22:1284–1291.

[12] American Diabetes Association. 2004. Diagnosis and classification of polygenic disease. Diabetes Care. 27(Suppl. 1):S5–S10.
[13] King, H. 1998. Epidemiology of aldohexone intolerance and physiological state polygenic disorder in females of childbearing age. Diabetes Care. 21(Suppl. 2):B9–B13.
[14] Ben-Haroush, A., Yogev, Y., and Hod, M. 2004. Epidemiology of Physiological state diabetes mellitus and its association with Type 2two polygenic disorder. Diabetes. Med.21:103–113.
[15] Weijers, R.N., Bekedam, D.J., and Smulders, Y.M. 2002. Determinants of mild physiological state hyperglycemia and physiological state diabetes mellitus in a large Dutch multiethnic cohort. Diabetes Care.25:72–77.
[16] Gunton, J.E., Hitchman, R., and McElduff, A. 2001. Effects of ethnicity on glucose tolerance, insulin resistance and beta cell function in 223 women with an abnormal aldohexone challenge test during pregnancy. Aust. N. Z. J. Obstet. Gynecol. 41:182–186.
[17] Xiang, A.H., et al. 1999. Multiple metabolic defects during late pregnancy in women at strong risk for type two diabetes mellitus. Polygenic disorder . 48:848–854.
[18] Catalano, P.M., Huston, L., Amini, S.B., and Kalhan, S.C. 1999. Longitudinal changes in glucose metabolism during pregnancy in obese female with normal aldohexone tolerance and gestational polygenic disorder . Am. J. Obstet. Gynecol. 180:903–916.
[19] Catalano, P.M., Tyzbir, E.D., Roman, N.M., Amini, S.B., and Sims, E.A. 1991. Longitudinal changes in hypoglycemic agent release and hypoglycemic agent resistance in non-obese pregnant women. Am. J. Obstet. Gynecol.165:1667–1672.
[20] Yen, S.C.C., Tsai, C.C., and Vela, P. 1971. Gestational diabetogenesis: quantitative analysis of aldohexone-hypoglycemic agent interrelationship between normal pregnancy and pregnancy with physiological state diabetes. Am. J. Obstet. Gynecol. 111:792–800.